Light Chain Bioscience Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
81
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
12
- Investments
-
1
Light Chain Bioscience General Information
Description
Operator of a biopharmaceutical company intended to discover multispecific antibody-based drugs. The company is focused on the development of drugs that are targeted for the treatment of inflammatory diseases, immune-related disorders, and cancer, enabling patients to get advanced treatment for their diseases and get cured efficiently.
Contact Information
Website
www.lightchainbio.comCorporate Office
- 15B Chemin du Pré-Fleuri
- Plan-Les-Ouates
- 1228 Geneva
- Switzerland
Corporate Office
- 15B Chemin du Pré-Fleuri
- Plan-Les-Ouates
- 1228 Geneva
- Switzerland
Light Chain Bioscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Light Chain Bioscience Comparisons
Industry
Financing
Details
Light Chain Bioscience Competitors (56)
One of Light Chain Bioscience’s 56 competitors is Virometix, a Venture Capital-Backed company based in Schlieren, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Genprex | Formerly VC-backed | Austin, TX | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Loxo Oncology | Formerly VC-backed | Stamford, CT |
Light Chain Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Light Chain Bioscience Patents
Light Chain Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250075000-A1 | Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity | Pending | 06-Sep-2023 | ||
| US-20240254234-A1 | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation | Pending | 21-Oct-2022 | ||
| AU-2023362569-A1 | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation | Pending | 21-Oct-2022 | ||
| US-20240254223-A1 | Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof | Pending | 02-Sep-2022 | ||
| AU-2023332193-A1 | Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof | Pending | 02-Sep-2022 |
Light Chain Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Light Chain Bioscience Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Light Chain Bioscience Investments (1)
Light Chain Bioscience’s most recent deal was a Corporate Asset Purchase with Novimmune (TZLS-501, A Fully Human Monoclonal Antibody). The deal was made on 01-Jan-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Novimmune (TZLS-501, A Fully Human Monoclonal Antibody) | 01-Jan-2017 | Corporate Asset Purchase | Buildings and Property |
Light Chain Bioscience FAQs
-
When was Light Chain Bioscience founded?
Light Chain Bioscience was founded in 1998.
-
Where is Light Chain Bioscience headquartered?
Light Chain Bioscience is headquartered in Geneva, Switzerland.
-
What is the size of Light Chain Bioscience?
Light Chain Bioscience has 81 total employees.
-
What industry is Light Chain Bioscience in?
Light Chain Bioscience’s primary industry is Biotechnology.
-
Is Light Chain Bioscience a private or public company?
Light Chain Bioscience is a Private company.
-
What is Light Chain Bioscience’s current revenue?
The current revenue for Light Chain Bioscience is .
-
How much funding has Light Chain Bioscience raised over time?
Light Chain Bioscience has raised $235M.
-
Who are Light Chain Bioscience’s investors?
Deutsche Messe and University of Geneva have invested in Light Chain Bioscience.
-
Who are Light Chain Bioscience’s competitors?
Virometix, Genprex, NexImmune, CytomX Therapeutics, and Loxo Oncology are some of the 56 competitors of Light Chain Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
